Nov 2, 6:30 AM ET
IDEXX Laboratories announced third-quarter revenue of $1,214 million and diluted earnings per share of $4.01, representing solid year-over-year gains. Driven by strong Companion Animal Group performance and innovation adoption, the company raised its full-year 2026 revenue and EPS outlook for shareholders.
- Third-quarter revenue reached $1,214 million, up 10% as reported and organic.
- Diluted earnings per share were $4.01, an increase of 18% as reported.
- Full-year 2026 revenue guidance was updated to a range of $4,741 million to $4,767 million.
- Full-year 2026 EPS outlook was raised to $14.96 to $15.16.
Read the filing on SEC.gov ↗
Aug 4, 6:32 AM ET
IDEXX reported second quarter 2026 revenue of $1,217 million, up 10% as reported and 9% organic, and diluted EPS of $4.27, up 18%. The company raised its 2026 EPS outlook to $14.69 to $14.94 from $14.45 to $14.90 and narrowed its full-year revenue guidance to $4,700 million to $4,745 million, which is $5 million higher at the midpoint.
- Q2 revenue of $1,217 million, up 10% as reported and 9% organic; CAG Diagnostics recurring revenue up 11% as reported
- Q2 EPS of $4.27, up 18% as reported and 15% comparable; includes $0.14 per share from share-based compensation tax benefits and $0.06 from currency
- 2026 EPS outlook raised to $14.69 to $14.94, from $14.45 to $14.90 previously
- Q2 operating margin of 35.0%, up 140 basis points as reported; 1,600 IDEXX inVue Dx placements in the quarter
Read the filing on SEC.gov ↗
May 5, 6:31 AM ET
IDEXX reported first-quarter 2026 revenue of $1,141 million, up 14% as reported and 11% organic, and EPS of $3.47, up 17% as reported. The company raised its 2026 revenue guidance to $4,675 million to $4,760 million and its EPS outlook to $14.45 to $14.90, and said CEO Jay Mazelsky is transitioning from the CEO role.
- Q1 2026 revenue $1,141 million, up 14% as reported and 11% organic; Companion Animal Group revenue up 15% as reported.
- Q1 EPS $3.47, up 17% as reported and 15% comparable; included a $0.05 loss on an equity investment and a $0.14 currency benefit.
- 2026 revenue guidance raised to $4,675 million to $4,760 million; EPS outlook raised to $14.45 to $14.90 from $14.29 to $14.80.
- Mazelsky said he is transitioning from the CEO role; the release says he will work with Mike Erickson on long-term growth.
Read the filing on SEC.gov ↗
Mar 26, 8:30 AM ET
IDEXX and Executive Vice President, Global Strategy and Commercial Nimrata Hunt agreed on March 24, 2026 that she will leave her role effective April 13, 2026, because her position is being eliminated. She will then provide advisory services until July 13, 2026, under a separation agreement that includes salary continuation and a two-year target bonus, and her unvested equity awards will be forfeited.
- Separation Date April 13, 2026; advisory services continue until Final Employment Date July 13, 2026
- Salary continuation for 104 weeks totaling $1,230,000, plus two years of target annual bonus totaling $984,000
- Unvested stock option, RSU and PSU awards will be forfeited; a $50,000 COBRA lump sum and $10,000 transition benefit are also included
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.